Company: ELV
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001156039-25-000046
Chunk: 59

Company: Elevance Health, Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 59
---
 determining the terms of equity awards, and we do not timethe release of material nonpublic information based on equity award grant dates.

We made our annual equity grant on March 1, 2024, in accordance with our standard practice, and filed a Current Report on Form 8-K on March 4, 2024 in connection with our participation at an investor conference. As described on page 52, the annual equity grant is made up of a combination of PSUs, stock options and RSUs, with stock options weighted at 25% of the annual award value.

| Name            |     | Grant Date |     | Number of securities underlying the award |     | Exercise price of the award ($/Sh) |     | Grant date fair value of the award |     |       | Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following disclosure of material nonpublic information |
| Gail Boudreaux  |     | 3/1/2024   |     |                                    32,480 |     |                            $499.11 |     |                         $4,199,989 |     | -0.15 | %                                                                                                                                                                                                                                                                                          |
| Mark Kaye       |     | 3/1/2024   |     |                                    10,633 |     |                            $499.11 |     |                         $1,374,953 |     | -0.15 | %                                                                                                                                                                                                                                                                                          |
| Peter Haytaian  |     | 3/1/2024   |     |                                     9,280 |     |                            $499.11 |     |                         $1,199,997 |     | -0.15 | %                                                                                                                                                                                                                                                                                          |
| Felicia Norwood |     | 3/1/2024   |     |                                     9,280 |     |                            $499.11 |     |                         $1,199,997 |     | -0.15 | %                                                                                                                                                                                                                                                                                          |
| Morgan Kendrick |     | 3/1/2024   |     |                                     8,312 |     |                            $499.11 |     |                         $1,074,825 |     | -0.15 | %                                                                                                                                                                                                                                                                                          |

#### Compensation and Talent Committee Report
The Compensation and Talent Committee has reviewed and discussed the Compensation Discussion & Analysis required by Item 402(b) of Regulation S-K